Clinical trial
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Efficacy and Safety of R333 6% Ointment Administered Topically to Discoid Lupus Erythematosus (DLE) and Systemic Lupus Erythematosus (SLE) Patients With Active Cutaneous Discoid Lesions
NCT01597050 is registered in ClinicalTrials.gov with Rigel Pharmaceuticals as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Efficacy and Safety of R333 6% Ointment Administered Topically to Discoid Lupus Erythematosus (DLE) and Systemic Lupus Erythematosus (SLE) Patients With Active Cutaneous Discoid Lesions
- Lead sponsor
- Rigel Pharmaceuticals
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- August 31, 2012
- Completion date
- September 30, 2013
- Enrollment
- 54 (actual)
- Sites
- 15
Conditions
As the registry lists them; a condition with its own page is linked.